Israeli clinical AI startup Aidoc raised $150 million in a funding round led by General Catalyst and Square Peg, with participation from four U.S. health systems. The company has more than 150 health system customers.
Sanofi’s Vicebio acquisition brings technology for developing vaccine combinations for multiple pathogens, such as RSV and hMPV. The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.
At a time when AI is reshaping pharma, Reverba Global CEO Cheryl Lubbert explained in an interview why empathy, context, and ethics still require a human touch.
We’d like to know what we can do to deliver more for our readers.
The keys are establishing a culture that applauds ideas and learns from “failures” rather than seeking to place blame, recognizing that the best ideas can come from any source, and benefiting from cross-functional discussion and challenge.
The American Heart Association’s venture arm invested in Auxira Health, a startup that embeds virtual clinical teams into cardiology practices to reduce physician burnout and expand patient access. By handling routine tasks like follow-up visits and medication refills, Auxira gives cardiologists the opportunity to focus on complex care without adding full-time staff.
Fourteen investors have committed to offering office hours at the HW Venture Center in July and August.
Break down the silos. Take control of your provider data.
A bipartisan group of lawmakers introduced legislation this week to extend CMS’ hospital-at-home waiver for five more years, allowing hospitals to continue delivering acute care in patients’ homes with Medicare reimbursement. The move comes as research shows this model reduces mortality and healthcare costs.
We're getting close to the July 19 deadline for submissions. Don't miss this opportunity to pitch your company to a team of investors at INVEST Digital Health in Dallas on September 18!
CoraVie Medical CEO Aimee Garza and Dr. Michael Bloch, a hypertension specialist and clinical advisor for the startup, talk about why the healthcare industry needs a better approach to blood pressure monitoring. CoraVie is developing an implantable device that measures patients’ blood pressure, operating in a similar way to continuous glucose monitors. Watch or listen now!
Samsung announced plans to acquire Xealth, a startup that helps hospitals integrate digital tools into clinical workflows, as part of its broader push into U.S. healthcare. The deal reflects growing provider demand for tech solutions and comes amid newfound optimism in the digital health exit market.
Explore top PTSD treatment centers in Arizona, offering personalized care, holistic therapies and expert support to help individuals heal and reclaim their lives.
Digital health funding held steady in the first half of 2025, with AI-focused startups capturing the majority of capital and driving rapid adoption among providers. The digital health space also saw two long-awaited IPOs as well as rising M&A activity, which are two signals of market maturity — but looming policy shifts may challenge long-term growth.
This week, CMS established a reimbursement code for Eko Health’s AI platform, which seeks to aid clinicians in the diagnosis of heart conditions. The goal behind the technology is to help catch heart disease earlier, when it’s easier to treat, and to make high quality diagnostic care more accessible.
Nordic Capital acquired a majority stake in health data platform Arcadia. Together, the two aim to accelerate the company’s mission of advancing value-based care through AI and data analytics. Arcadia CEO Michael Meucci views the deal as both a validation of the company’s strategy and part of a broader wave of healthcare investments focused on interoperability, AI and payment reform.
Ochsner Health is expanding its use of Latent Health’s AI platform after its reduced medication prior authorization times to just 4-5 minutes. The technology is designed to both streamline pharmacists’ workflows as well as improve patients’ access to medications.
Instead of an engineered peptide to activate gut receptors to trigger metabolic effects, Syntis’s technology forms a coating in intestines that has the effect of redirecting nutrients, mimicking an effect of gastric bypass surgery. In other obesity medicine news, Protagonist Therapeutics revealed a drug candidate that puts it in competition with Novo Nordisk and Eli Lilly, among others.